Founded in 2005, Korea Institute for Pharmaceutical Policy Affairs, KIPPA, is a non-profit, public foundation, approved by the Korean Ministry of Health and Welfare. The institute is contributed by three relevant parties, the Korean Pharmaceutical Association (KPA), the Korea Pharmaceutical and Bio-Pharma Manufacturers Association (KBPMA), and the Korea Pharmaceutical Distribution Association (KPDA).

KIPPA is a leading research center, which aims to promote public health through the development of policy regarding the rational use of medicines, pharmacy education, pharmacy practice, pharmaceutical industry, and pharmaceutical supply and distribution. In particular, we begin to develop ¡®a community pharmacy model as a health promotion center for community members¡¯. We are collecting and analysing big data accordingly to develop pharmacy-based policies, which pursue maximised pharmacy practice for all the Koreans.

In consequence, KIPPA will consistently implement research tailored to the promotion of health in the nation and worldwide. We kindly ask for supports from our fellow pharmacists, public and associations.

If you have any further enquiries about the institute or research in English, please contact us via e-mail (kippa.org@gmail.com).

Thank you.

Office Address
3FL, 194, Hyoryeong-ro, Seocho-gu, Seoul, Repbulic of Korea

ÇöÀçÀ§Ä¡ : Home : ¾Ë¸²¸¶´ç : ¿¬±¸¼Ò ´º½º
   
¾Ë¸²¸¶´ç
°øÁö»çÇ×
º¸µµÀÚ·á
ÀÎÀçä¿ë
 
 
Á¦   ¸ñ [Àϰ£º¸»ç] ¡®Äڷγª19, Àü ±¹¹Î 60% Á¢Á¾ÇÒ ¹é½Åȯ°æ ±¸ÃàµÅ¾ß¡¯
³»   ¿ë
¡®Äڷγª19, Àü ±¹¹Î 60% Á¢Á¾ÇÒ ¹é½Åȯ°æ ±¸ÃàµÅ¾ß¡¯Á¦¾àÇùȸ, ¡°2Â÷ ¿þÀÌºê °¡Á¤ ½Ã, Á¦Ç° °³¹ßÈ­ ´Ü°è±îÁö Á¤ºÎ Áö¿ø Çʿ䡱

[ÀÇÇнŹ®¡¤Àϰ£º¸»ç=±è¹ÎÁö ±âÀÚ] ¡°±¹³»±âÁØÀ¸·Î Áý´Ü¸é¿ªÀÇ È¿°ú¸¦ °¡Áú ¼ö Àִ ¹é½Å ºñÃà·®Àº ¾à 50%ÀÌ°í ¾ö°ÝÇÑ Á¶°ÇÇÏ¿¡¼­´Â 60%°¡ ÇÊ¿äÇÏ´Ù¡±

¹ÚÈ£Á¤ ±³¼ö

27ÀÏ, ¹ÚÈ£Á¤ °í·Á´ë ½ÄǰÀÚ¿ø°æÁ¦Çаú ±³¼ö´Â ´ëÇѾà»çȸ°ü¿¡¼­ ¿­¸° ¡®ÀǾàǰÁ¤Ã¥¿¬±¸¼Ò 1Â÷ Á¤Ã¥Æ÷·³¡¯¿¡¼­ À̰°ÀÌ ¹àÇû´Ù.

¹Ú ±³¼ö¿¡ µû¸£¸é COVID-19»çÅ·ΠÀÎÇØ Á¦¾à»çµéÀº ¹é½Å°ú Ä¡·áÁ¦ °³¹ß¿¡ ¶Ù¾îµé°í ÀÖÁö¸¸ ºÎ´ã°¨À» ¶°¾ÈÀ» ¼ö ¹Û¿¡ ¾ø´Ù´Â °ÍÀÌ´Ù. Àü¼¼°è¿¡¼­ °³¹ßµÇ°í Àִ ¾à¹°ÀÇ 80% ÀÌ»óÀº ÀÓ»ó ÀÌÀü Ãʱâ´Ü°è¿¡¼­ °³¹ßµÇ°í ÀÖÀ¸¸ç µ¿ÀÏÇѠŸ±ê¿¡¼­ ¿¬±¸µÇ´Â ¾à¹°ÀÌ À־๰ÀÇ È¿°ú¿Í ¾ÈÀü, ÆíÀ̼ºµµ °í·ÁÇØ¾ß ÇѴٴ °Í. Á¤ºÎ°¡ ÃÖÀû ºñÃà±Ô¸ð¸¦ ÆÄ¾ÇÇØ Çö½ÇÀûÀΠÁö¿øÃ¥À» ¸¶·ÃÇØ¾ß ÇѴٴ ¸ñ¼Ò¸®°¡ ³ª¿À´Â ¹è°æÀÌ´Ù.

¹ÚÈ£Á¤ ±³¼ö´Â ¡°ÃÖÀûºñÃà±Ô¸ð´Â ¹é½Å¼Ò¿äºñ¿ë°ú »çȸÀûÀΠÆíÀÍ µîÀ» °í·ÁÇØ¾ß ÇÑ´Ù. ±âº»ÀûÀ¸·Î ¹é½ÅÀ¸·Î ÀÎÇØ ³ªÅ¸³ª´Â »çȸÀû ÆíÀÍÀ̳ª ºñ¿ë µî »çȸ°æÁ¦ÀûÀΠȿ°ú¸¦ ¿ªÇиðÇü°ú ¿¬°èÇÑ °ÍÀÌ °æÁ¦¿ªÇиðÇüÀÌ´Ù¡±¸ç ¡°±âÃÊÀç»ý»ê¼ö(R0)´Â ¿ªÇРÁ¶»ç¿¡¼­ °¡Àå ±âÃÊÀûÀ̰í Áß¿äÇÑ Á¤º¸·Î 1Â÷ °¨¿°ÀÚ°¡ Æò±ÕÀûÀ¸·Î °¨¿°½Ãų ¼ö Àִ 2Â÷ °¨¿°ÀÚÀÇ ¼ö¸¦ ÀǹÌÇÑ´Ù¡±°í ¼³¸íÇß´Ù.

À̾״ ¡°·ÎÁö½ºÆ½ ºÐ¼® °á°ú, ¹é½Å°³¹ß ¼º°ø ½Ã ÇÊ¿äÇÑ ºñÃà ±Ô¸ð´Â R0 ±âÁØÀ¸·Î °¨¿°°¡´É Àα¸ÀÇ 52%, ¹é½ÅÀÇ ÆíÀÍ-ºñ¿ëÀ» °í·Á½Ã °¨¿°°¡´É Àα¸ÀÇ 62%´Ù¡±°í µ¡ºÙ¿´´Ù.

À̿͠°ü·ÃÇØ Çѱ¹Á¦¾à¹ÙÀÌ¿ÀÇùȸ ¾ö½ÂÀΠ»ó¹«´Â ¡°Àü±¹¹Î 60%°¡ Á¢Á¾À» Çߴٴ °ÍÀº ¾ÈÀüÇϰí À¯È¿ÇÑ ¹é½ÅÀÌ ³ª¿Ô´Ù´Â Àǹ̴Ù. ¹é½ÅÀº °Ç°­ÇÑ »ç¶÷ÇÑÅ× Åõ¿©Çϱ⠶§¹®¿¡ ¾ÈÀü¼ºÀÌ ´ãº¸µÅ¾ß Çϴ ºÎºÐÀÌ ÀÖ´Ù¡±¸ç ¡°Àü¼¼°èÀûÀ¸·Î 2Â÷ ¿þÀ̺갡 ¿Ô´Ù°í °¡Á¤Çϸé 60%¿¡ ÇØ´çÇϴ »ç¶÷µéÀÌ ´Ù ¸ÂÀ» ¼ö Àִ ¹é½Å È®º¸°¡ °¡´ÉÇѰ¡¿¡ ´ëÇÑ Àǹ®ÀÌ ÀÖ´Ù¡±°í ¸»Çß´Ù.

±×·¯¸é¼­ Á¤ºÎ°¡ Àû±ØÀûÀ¸·Î Á¦¾à»çÀÇ Ä¡·áÁ¦ °³¹ßÀ» Áö¿øÇØ ÁÙ °ÍÀ» °­Á¶Çß´Ù.

¾ö »ó¹«´Â ¡°°¨¿°º´ »çÅ¿¡¼­´Â Ä¡·áÁ¦ °³¹ß ÁߠȯÀÚ°¡ ¾ø¾î¼­ Á¾½ÄµÇ´Â »çŰ¡ Ç×»ó ¹ß»ýÇ߱⠶§¹®¿¡ ¾àÀÌ ³ª¿Ã ¼ö ¾ø¾ú´Ù. °æÁ¦¼ºÀÌ ¾ø´Â °¨¿°º´ Ä¡·áÁ¦¿Í °°Àº ºÎºÐ¿¡¼­´Â ±¹°¡°¡ °³ÀÔÇØ¾ß ÇÑ´Ù¡±¸ç ¡°ÇöÀç Á¦¾à»çµéÀÌ ¹é½Å Á¦Ç° °³¹ß¿¡ ³ë·ÂÀ» ´ÙÇϰí ÀÖÁö¸¸ È¯ÀÚ°¡ ¾ø¾î¼­ ÇØ¿ÜÀÓ»óÀ¸·Î ³ª°¡¾ß Çϴ ½ÇÁ¤¡±À̶ó°í Åä·ÎÇß´Ù.

À̾״ ¡°ÇöÀç Á¤ºÎ°¡ ÀÓ»ó 1¡¤2»óÀ» Áö¿øÇØÁÖ°í Àִµ¥ 3»ó ÀÌÈÄ Á¦Ç° »ý»ê±îÁö´Â Áö¿øÇØÁØÀûÀÌ ¾ø´Ù¡±¸ç ¡°°á±¹ 2Â÷ ¿þÀ̺ê±îÁö ¿Â´Ù°í °¡Á¤Çϸé Á¦Ç° °³¹ßÈ­±îÁöµµ Á¤ºÎ°¡ Áö¿øÇØÁà¾ß ÇÑ´Ù¡±°í ¾ð±ÞÇß´Ù.

±è¹ÎÁö ±âÀÚ  mjkim@bosa.co.kr

[±â»çÃâó] http://www.bosa.co.kr/news/articleView.html?idxno=2127605




 

¹øÈ£ ÷ºÎ Á¦¸ñ ÀÛ¼ºÀÚ ÀÛ¼ºÀÏ Á¶È¸
39 [¸Þµð°ÔÀÌÆ®] "Äڷγª19 À¯Çà ³¡³ªµµ ¹é½Å ¿¬±¸°³¹ß °è¼Ó..3000¸¸¸íºÐ ±¹°¡ ºñÃà" ±è¼±Èñ 2020-05-29 1099
38 [¾à¾÷½Å¹®] ¡°Äڷγª19 Ä¡·áÁ¦¡¤¹é½Å, °æÀïÁ¦Ç° ºñ±³¿ìÀ§ È®º¸ Çʼö¡± ±è¼±Èñ 2020-05-29 1138
37 [¾à¾÷½Å¹®] Äڷγª19 ¹é½Å º¸À¯·® Àü ±¹¹Î 52~62% ¼öÁØ µÅ¾ß ±è¼±Èñ 2020-05-29 927
36 [ÄíŰ´º½º] ¡°Äڷγª19 ¹é½Å °³¹ß¡¤ºñÃà, Á¤ºÎ °³ÀÔ ÇʼöÀû¡± ±è¼±Èñ 2020-05-29 796
35 [Àϰ£º¸»ç] ¡®Äڷγª19, Àü ±¹¹Î 60% Á¢Á¾ÇÒ ¹é½Åȯ°æ ±¸ÃàµÅ¾ß¡¯ ±è¼±Èñ 2020-05-29 671
34 [µ¥Àϸ®ÆÊ]"±¹¹Î 60%°¡ ¹é½Å ¸Â¾Æ¾ß Äڷγª19 À¯Çà ¸·´Â´Ù" ±è¼±Èñ 2020-05-29 712
33 [¾à»ç°ø·Ð] ÀǾàǰÁ¤Ã¥¿¬, ¡®Äڷγª19 Ä¡·áÁ¦ ¹× ¹é½Å°³¹ß¡¯ ÁÖÁ¦ Æ÷·³ °³ÃÖ ±è¼±Èñ 2020-05-29 690
32 [´ëÇѾà»çÀú³Î]ÀǾàǰÁ¤Ã¥¿¬±¸¼Ò ¸®Æ÷Æ®_°í·ÉÈ­¡¤¸¸¼ºÁúȯÀ¸·Î ÀÎÇÑ ÀǾàǰ ¼Òºñ º¯È­ 2 ±è¼±Èñ 2020-05-25 777
31 [´ëÇѾà»çÀú³Î] ÀǾàǰÁ¤Ã¥¿¬±¸¼Ò ¸®Æ÷Æ®_2019³â OECD ÇÑ´«¿¡ º¸´Â °Ç°­(Health at a Glance) 1 ±è¼±Èñ 2020-05-25 877
30 [µ¥Àϸ®ÆÊ] ÀǾàǰÁ¤Ã¥¿¬±¸¼Ò, Áúº» ¹ßÁÖ ±¹°¡¹é½Å ¿¬±¸ Âü¿© ±è¼±Èñ 2020-05-21 994
29 [º¸°Ç´º½º] ÀǾàǰÁ¤Ã¥¿¬±¸¼Ò ¡®±¹°¡¹é½Å ¼ö±Þ ¸ð´ÏÅ͸µ ¹× ¼ö¿ä ¿¹Ãø ¸ðµ¨¸µ¡¯ »ç¾÷ Âü¿© ±è¼±Èñ 2020-05-21 841
28 [¸ÞµðÆÄ³ª´º½º] ÀǾàǰÁ¤Ã¥¿¬±¸¼Ò, ±¹°¡¹é½Å ¼ö±Þ ¸ð´ÏÅ͸µ »ç¾÷ Âü¿© ±è¼±Èñ 2020-05-21 699
27 [Àϰ£º¸»ç] ¿ì¸®³ª¶ó ÀǾàǰ ¼Òºñ Áõ°¡À² ¡®ÃÖ»óÀ§¡¯ ±è¼±Èñ 2020-05-15 966
26 [µ¥Àϸ®ÆÊ] Àα¸ 10¸¸¸í´ç ¾à±¹¼ö, OECD Æò±Õº¸´Ù 1.4¹è ³ô¾Æ ±è¼±Èñ 2020-05-15 1197
25 [¸Þµð°ÔÀÌÆ®]¾à±¹ 1ÀÎ °æ¿µ ¹æ½Ä À§ÁÖ.."OECD ´ëºñ ¾à±¹ ¼ö´Â ¸¹Áö¸¸ ¾à»ç´Â Æò±Õ ÀÌÇÏ" ±è¼±Èñ 2020-05-15 789

ÀÌÀü 10ÆäÀÌÁö [1]  [2]  [3]  [4]  [5]  [6]  [7]  [8]  [9]  ´ÙÀ½ 10ÆäÀÌÁö

 
 

¼­¿ï ¼­Ãʱ¸ È¿·É·Î194, 3Ãþ (Àç)ÀǾàǰÁ¤Ã¥¿¬±¸¼Ò TEL : 02) 3474-5301 / FAX : 02)3474-5306

COPYRIGHT (C) 2006 KOREA INSTITUTE FOR PHARMACEUTICAL POLICY AFFAIRS ALL RIGHTS RESERVED. FOR MORE INFORMATION MAL kippa.org@gmail.com

±âºÎ±Ý ¾È³»